UroAlert - GU Oncology Weekly

June 11, 2026

Videos

Peer-to-Peer Clinical Conversations

Intravesical Anti-Nectin-4 ADC in NMIBC: Phase 1/2 Trial Design and Tolerability - Joshua Meeks

Joshua Meeks

Joshua Meeks describes a phase 1/2 trial of an intravesical anti-nectin-4 antibody-drug conjugate with a topoisomerase inhibitor payload.

Analysis of the Phase III CAPItello-281 Trial: Capivasertib plus Abiraterone in PTEN-Deficient mHSPC - Daniel George

Daniel George

Neeraj Agarwal hosts Daniel George to discuss the CAPItello phase three trial examining capivasertib combined with abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.

Beyond the Abstracts

Outcomes of Immune Checkpoint Inhibitor Rechallenge in Advanced Urothelial Carcinoma: Results from a Global Real-World Evidence Study - Beyond the Abstract

Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma- Beyond the Abstract

Conference Coverage

ASCO 2026: UTOPIA: A Phase 3 Trial of UGN-103, an Intravesical Mitomycin Reverse Thermal Hydrogel, in Recurrent Low Grade Intermediate Risk NMIBC

ASCO 2026: Molecular Characterization of Residual Disease Post-Neoadjuvant Sacituzumab Govitecan, Pembrolizumab, or Their Combination in Patients with MIBC

ASCO 2026: Assessing Responses to UGN-102 Across EORTC Recurrence Score Groups in Patients with Recurrent Low Grade Intermediate Risk NMIBC (ENVISION Trial)

AUA 2026: Planning to Plenary: Behind the Scenes of Leading Urology Clinical Trials

AUA 2026: Long-Term Follow-Up Results of aMVAC Arm of ECOG-ACRIN EA8141: a Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High-Grade Upper Tract Urothelial Carcinoma

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

External Validation of A Decision Tree Model for Predicting Cancer-Specific Mortality After Radical Cystectomy: A Multi-Center Study in South-East Spain.

Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan.

Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.

Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer.

Photocure and Artera to Partner on Digital Pathology AI Test Evaluation for Bladder Cancer

Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics

Effect of marital status on years of life lost from metastatic bladder cancer according to sex and race/ethnicity.

Impact of CKD on perioperative outcomes following TURBT: a national NSQIP analysis.

Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer.

Sarcopenia Weakens the Benefit of Bacillus Calmette-Guérin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study.

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.

Collecting electronic patient-reported outcomes via smartphone text messages in a bladder cancer RCT: A feasibility study.

Penile & Urethral Cancers

Single-cell immunoprofiling reveals a dysfunctional-like immune microenvironment and malignant phenotype in aging penile squamous cell carcinoma.

Danish National Penile Cancer Database, DaPeCa-Data: Characteristics, Management, and Survival 2000-2025 - Beyond the Abstract

Renal Cancer

Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III Renal Cell Carcinoma.

Comparison of partial nephrectomy to radical nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian Multi-Institutional Collaborative.

Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney Cancer.

ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinoma.

Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time-Varying Effects.

Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.

Rates of adjacent organ invasion in non-metastatic renal cell carcinoma: a population-based study.

First-in-human ex-vivo validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL - PNRR-POC-2023-12377493).

Genitourinary Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2025: Advances in Renal Cell Carcinoma and Muscle-invasive Bladder Cancer.

Updates and controversies in contemporary grading of clear cell renal cell carcinoma and papillary renal cell carcinoma.

Sutureless Robotic-Assisted Partial Nephrectomy: A Propensity Score-Matched Analysis (UroCCR N.158) - Beyond the Abstract

Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium - Beyond the Abstract

Prostate Cancer

Delphi consensus on ex vivo fluorescence confocal microscopy in robot-assisted radical prostatectomy.

Real-Time Assessment of Surgical Margins During Radical Prostatectomy: A Comprehensive Review.

Proton Beam Therapy in Prostate Cancer: Clinical Evidence, Controversies and Future Directions.

The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.

Impact of Homologous Recombination Repair Gene Mutations on Survival in Metastatic Prostate Cancer: A Real-World Analysis from an observational database.

Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer.

Enhanced Telehealth in Prostate Cancer.

Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI.

Salvage prostatectomy for locally recurrent prostate cancer after radiation: a narrative review of indications, outcomes, and surgical advancements.

Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL.

177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil.

Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients.

Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria.

Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report.

High folate receptor expression is associated with aggressive features in prostate cancer with low prostate-specific membrane antigen expression.

Progression-free Survival Following Primary Staging with [18F]PSMA-1007-PET/ceCT Versus Na[18F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial.

Younger Age Is Associated With Early Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy.

Aglatimagene Besadenovec (CAN-2409) with Radiotherapy for Patients with Localised Prostate Cancer: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial - Beyond the Abstract

Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)

Prospective Multicenter Randomized Controlled Trial of Stabilized Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results

A decision-oriented framework for genomic testing across the prostate cancer continuum.

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Years of life lost from metastatic prostate cancer according to household income.

Enhancing foundation model transfer for prostate cancer detection with patch-level contrastive learning.

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

Stage-Specific Regulation of DNA Damage Repair by the Circadian Regulator, CRY1, in Prostate Cancer.

Adding Immunotherapy to Radiation Improves Disease-Free Survival in Localized Prostate Cancer

Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer.

Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer.

A harmonized single-cell RNA-seq atlas of human localized and metastatic prostate cancers and benign tissues.

Impact of Prior Treatments on Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer: A Real-World Analysis in the United States.

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial - Beyond the Abstract

Neoadjuvant Fc-Enhanced Anti-CTLA-4 Targets Tregs to Augment Androgen Deprivation in High-Risk Prostate Cancer: A Randomized Phase I Trial - Beyond the Abstract

Testicular Cancer

Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes.

Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors study.

Spontaneous miscarriage after intracytoplasmic sperm injection with frozen sperm of patients with testicular germ cell tumour.

Integrating the relevance of sleep into testicular-cancer survivorship care.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC